Teaming up again with the great @VerwerftJan to share our experience with #echoCPET in #HFpEF. This hot-of-the-press paper @ESC_Journals demonstrates myriad of opportunities for diagnosis & treatment, far beyond #SGLT2i only. Tweetorial below!
In #HFpEF, early & correct diagnosis are important, #phenotyping is everything. There are a lot of mechanisms for dyspnoea involved
Current @ESC_Journals paper goes one step further: "In patients with confirmed HFpEF or probability >90% according to well-validated HFpEF scores (both are complimentary in our view), why #echoCPET within a dedicated #dyspnoea clinic? What is the impact of findings?"
1. Further diagnostic work-up ! #HFpEF has a lot of mimickers that deserve to be ruled out, in 9/10 patients we searched further for causes of dyspnoea, on average 2 diagnostic exams per patient! #cardiomyopathy#amyloid#CAD#lungdisease
2. Medical treatment changes !
In virtually all patients, one can optimize therapies... We change on average 3 meds! #SGLT2i & #spironolactone are obvious ones, but #hypertension & #lipids should be within targets!
Also, I single out reducing/stopping #betablockers, done in ~60%!
3. Tackle comorbidities in 1 stop !
- Obesity is a treatable disease nowadays: #GLP1agonists, sometimes surgery
- Iron deficiency present in 40% (need more data in #HFpEF for R/, but we do often do provide IV iron)
- Too many patients w #diabetes to leave only to endocrinologists
"Don't blame the patient for not caring for themselves, blame yourself for not taking the action that is necessary"
Pro-active = making a difference together
4. Cardiac interventions !
So much easier to stop betablockers in #HFpEF after #AFib ablation. However, first get the meds right and #decongest proberly, more success!
In selected patients pacing & valvular interventions are useful, but ONLY AFTER getting the other things right!
Do You have a dyspnoea clinic for #HFpEF at your place?
• • •
Missing some Tweet in this thread? You can try to
force a refresh
From #ADVOR population, we included 462 or 89% of patients with 2 correctly performed consecutive urine collections and urine sodium concentration (UNa) available.
Natriuresis:
- UNa [mmol/L] ~ diuretic efficiency
- Total natriuresis [mmol] ~ ECV & interstitial Na buffer removed
#Acetazolamide, after multivariate adjustment, was strongest predictor of #natriuresis in #ADVOR:
UNa + 16 mmol/L
Total natriuresis +115 mmol
👊 within 2 days !!!
👍 much stronger than effect on urine output itself
What is your take on #vasodilators in acute #HeartFailure? The upcoming November issue of #EHJACVC will bring you a PRO/CON "Vasodilator therapy in acute heart failure revisited"
As our PRO paper was published in advanced access, a sneak preview Tweetorial below...
First some background...
Current @escardio guidelines state (IIb, B): "In patients with AHF and a systolic blood pressure (SBP) >110 mmHg, intravenous vasodilators may be considered as an initial therapy to improve symptoms and reduce congestion."
Only 1 flowchart has them in...
So far, I consider this a fair recommendation... In hyper/normotensive pulmonary oedema, they might be helpful in some cases, with their main benefit a reduced need for (non-)invasive ventilation!
Extremely proud that our journal offers a platform to 3 great clinicians & Twitter educators. I always learn from them...
A strong argument is made to switch mainstream thinking in #AKI away from the fallacious concept of fluid responsiveness in all to a primary assessment of fluid tolerance.
Probably the most important thing I have learned on Twitter: #VExUS
Why do I like #VExUS so much? Because it really changed my everyday practice... Portal vein became part of my standard #echocardiography assessment.
And that's what we want to achieve with this review, offer something directly applicable at your bedside!
For those who can't get enough from #ADVOR, below the promised Tweetorial!
Acetazolamide in acute #HeartFailure w volume overload on background high-dose loop diuretics:
👍Increases diuresis & natriuresis
👍More euvolemia after 3 days & discharge
👍⬇️LOS #ESCCongress#Cardiology
First, the unsung hero's of this trial, done with a little bit over 2 million €, bargain for largest diuretic #RCT ever! @KatrienTartagl2 & her team, with only 3FTE, they ran the most successful trial in #AHF @PieterMartensMD & @JeroenDauw who did most fieldwork
👏
How did we come up with the idea? Actually, cause we all love #physiology. Credits go to Prof. Em. Paul Steels who teached us all how kidneys work. @GLW_UHasselt
65% of sodium is reabsorbed in the proximal tubules, can be up to 85% in #HeartFailure
Do You keep slamming Your face because You missed the 1st #HFA@escardio Clinical Practice Update Course on #HeartFailure, orchestrated masterfully by MC Mullens?
I'll release just a teaser under the form of a clinical case below. You might call on my partners in crime @Ph_Bertrand & @petranijst to do the same...
How is diuretic efficiency changing with severity of #CKD? What is its prognostic relevance?
Read our new paper in CardioRenal Medicine!
@WilsonTangMD@BammensBert
Also thanks to Jeff Testani, Pieter Martens & Dirk Kuypers for their help with the paper...
We used 3 metrics of diuretic efficiency, based on urine output, natriuresis & chloruresis.
Irrespectively of metric, loop diuretic efficiency decreased significantly from KDIGO class IV, while remaining relatively preserved in less advanced CKD.
Patterns were similar for furosemide versus bumetanide (very little patients were on torsemide, which is hardly used in Belgium). Yet, baseline characteristics were strikingly different with bumetanide users older with higher cardiovascular risk.